BioSpain 2014

7th International Meeting on Biotechnology

Pro Chile invites BIO 2014 (limited spaces)

A great opportunity to show the world promoting services and projects related to the biotechnology industry.

Fundación Biociencia: pioneering research of extremophiles in Latin America

More and more companies are turning to advances in biotechnology to improve industrial processes and it is being used by Chilean researchers.

Fundación Chile and AEON Biogroup, with funding from CORFO, invite you to the Second International Seminar Microalgae: A New Nutrition for Humanity.

 

Nexos Chile-USA

nexos-chileusa

Nexos Chile-USA es una agrupación que coordina y reúne a chilenos que se encuentran desarrollando su carrera científica en Estados Unidos, cuyo fin es crear redes que fortalezcan y contribuyan al desarrollo científico de Chile. Nexos nace en respuesta a las inquietudes de cómo establecer colaboraciones e intercambios entre ambos países y cómo facilitar la reinserción laboral en el mundo científico chileno. Junto a esto, Nexos pretende representar a los científicos chilenos en Estados Unidos y generar instancias concretas de colaboración científica. Además, deseamos participar activamente en la resolución de las inquietudes y problemáticas intrínsecas al desarrollo de nuestra profesión. Finalmente, queremos generar instancias de discusión y ser un aporte concreto en la generación de políticas científicas que contribuyan al desarrollo de Chile.

read more

Invitación BioSpain 2014

invitacion_biospainOK

Asembio, a través de su Marca Sectorial Chilebiotech, tiene el agrado de invitarle a participar en el evento BioSpain 2014, a realizarse desde el 24 al 26 de septiembre del presente, que se llevará a cabo en Santiago de Compostela, España.

Además informamos que tenemos un pack de viaje que incluye lo siguiente:
- Pasajes aéreos ida y vuelta.
- Alojamientos
- Entrada al evento
- Visita a un Parque Tecnológico y/o empresas del rubro.

Descuentos adicionales para socios de Asembio.

Los cupos son limitados, si le interesa participar pongase en contacto con nosotros.
Para mayor información, contactese en epalacios@asembio.cl con Elena Palacios.

read more

Study: Marine pest provides advances in maritime anti-fouling and biomedicine

A team of biologists, led by Clemson University associate professor Andrew S. Mount, performed cutting-edge research on a marine pest that will pave the way for novel anti-fouling paint for ships and boats and also improve bio-adhesives for medical and industrial applications. The team’s findings, published in Nature Communications, examined the last larval stage of barnacles that attaches to a wide variety of surfaces using highly versatile, natural, possibly polymeric material that acts as an underwater heavy-duty adhesive.

read more

BioSpain 2014

biospain 26-1-013 ULTIMO

BIOSPAIN is the largest biotech event organized by a national bioindustry association in Europe and one of the largest in the world by the number of one-to-one meetings (2.775) and companies participating (762).

BIOSPAIN is organized by ASEBIO, the Spanish Bioindustry Association and each edition is co-organized by a local institution from the host city/region. On the 2014 edition, Biospain is co-organized by a number of local institutions under the lead of Xunta de Galicia, the Government of the Autonomous Region of Galicia.

read more

C. difficile vaccine proves safe, 100 percent effective in animal models

140731145933-large

An experimental vaccine protected 100 percent of animal models against the highly infectious and virulent bacterium, Clostridium difficile, which causes an intestinal disease that kills approximately 30,000 Americans annually.

In the study, the vaccine protected the mice and non-human primates against the purified toxins produced by C. difficile, as well as from an orogastric spore infection, a laboratory model that mimics the human disease, after only two immunizations.
“Animals that received two immunizations did not get sick or show signs of C. difficile-associated disease,” says corresponding author Michele Kutzler, of Drexel University College of Medicine, Philadelphia.

read more